Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2014. The report details a specific share repurchase transaction executed on June 2, 2014, authorized by shareholders at the Annual General Meeting on May 7, 2014.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 627,000 Ordinary Shares of 25 pence each.
- Purchase Price Range: High of 1,607.50 pence; Low of 1,589.50 pence per share.
- Treasury Shares Held: 494,710,714 shares (9.25% of total issued share capital).
- Treasury Shares (Including Unsettled): 496,520,414 shares (10.22% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,855,980,304 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 627,000 shares for treasury. Consequently, the percentage of total voting rights held in treasury increased to 10.22% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure regarding share ownership and repurchase authority.
Investor Verification Checklist
- Verify the total number of shares in issue (4,855,980,304) for calculating disclosure thresholds under FCA rules.
- Confirm the current treasury share percentage (9.25% settled, 10.22% including unsettled) for voting rights calculations.
- Review the price paid per share (approx. 1,589.50 to 1,607.50 pence) against market prices on June 2, 2014.